Shionogi Completes $2.5B RADICAVA Rights Acquisition

Shionogi has completed its acquisition of global rights to RADICAVA (edaravone) from Tanabe Pharma Corporation in a $2.5 billion deal. The transfer includes intellectual property and sales rights, strengthening Shionogi’s rare disease position in treatments for Amyotrophic Lateral Sclerosis.

Shionogi integrated more than 100 Tanabe team members and related infrastructure immediately to support continuity of care for ALS patients. RADICAVA is FDA-approved and used to treat more than 22,000 ALS patients in the United States, including intravenous and oral formulations.

Shionogi expects the transaction to be immediately accretive in fiscal year 2026, contributing approximately $700 million in annual global sales, and it views the acquisition as a commercial platform for future rare-disease launches.